Clinical Brief: The Disproportionate Burden of ATTR-CM In African Americans

ATTR cardiac amyloidosis (ATTR-CM) is a complex disease that remains challenging to diagnose and treat, and disproportionally affects African American patients. Low awareness about the disease, and limited therapeutic options are significant barriers to optimal care, however, significant advances have been made in the development of novel targeted-therapeutics that may improve patient outcomes. This clinical brief will review some of those advances in order to increase awareness about current gaps and disparities in ATTR-CM.

Target Audience

This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), registered nurses, nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, dieticians, and other allied health professionals.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Define the pathophysiology, prevalence, and types of ATTR-CM.
  • Recognize the disproportionate burden of ATTR-CM in African Americans and the significance of Val122l mutation.
  • List current and emerging screening and diagnostic approaches aimed to optimize the early identification of African American patients with ATTR-CM.
  • Review the different options for the treatment of ATTR-CM, including new and emerging novel targeted agents.

Additional Information

PDF icon Clinical Brief PDF400.69 KB
Course summary
Available credit: 
  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit
  • 0.50 ANCC
  • 0.50 CDE
  • 0.50 Participation
Course opens: 
Course expires: 

Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor of Medicine
John W. Deming Department of Medicine
Tulane University School of Medicine
New Orleans, LA

Dr. Ferdinand discloses the following: 

  • Consulting Fee (e.g., Advisory Board): Amgen, Novartis, Medtronic, Boehringer Ingelheim, Quantum Genomics, Janssen

0.5 hour

This activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc


This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians

Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 0.5 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity. 

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Credit Designation
Global Education Group designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number (UAN): 0530-9999-22-206-H01-P

This is a knowledge-based activity. 

Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 0.5 Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012

CDR learners may submit their program evaluation directly to the CDR.

For information about the accreditation of this program, please contact Global at 303-395-1782 or


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or ManagerReported Financial Relationship
Rhys Williams, MSN, FNP-C, RNNothing to disclose.
Lindsay BorvanskyNothing to disclose.
Andrea FunkNothing to disclose.
Liddy KnightNothing to disclose.
Ashley CannNothing to disclose.
Karin McAdamsNothing to disclose.
Shpetim Karandrea, PhDNothing to disclose.
Neha Agarwal, PhDNothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


This activity is complimentary and available during the period September 19, 2022 through September 19, 2023. Participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 70% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be be available for print. For questions about receiving certificates, please contact us at 

For questions about the accreditation of this activity, please contact Global at 303-395-1782 or

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

Available Credit

  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit
  • 0.50 ANCC
  • 0.50 CDE
  • 0.50 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.